7 results about "Streptococcal strain" patented technology

This disclosure relates to immunogenic compositions comprising attenuated and / or dead streptococcal bacterial strains, including modifications that reduce, decrease, or prevent the functional expression of LytC (or its homologues). Such compositions may be used in vaccine compositions. Immunogenic compositions and / or vaccine compositions may be used in methods for inducing an immune response to at least one target streptococcal species and / or its serotype, and / or for preventing or mitigating infections and / or diseases or conditions in a subject caused by at least one target streptococcal species and / or its serotype.

Disclosed are a novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain, a composition containing the same for prevention or alleviation of an oral disease, and oral probiotics, and specifically, the novel Streptococcus salivarius (S. salivarius G7, KCCM13161P) strain can prevent, treat, and alleviate periodontal diseases through strong antibacterial and antiinflammatory activities against periodontal disease-causing strains, prevents, treat, and alleviates dental caries through strong antibacterial activity against dental caries-causing strains and biofilm formation inhibitory ability, and suppress halitosis caused by oral diseases, thereby contributing to oral health improvement.

The present invention relates to a Streptococcus zooepidemicus SMT013 strain having increased hyaluronic acid production capacity, a variant thereof, and a method for producing hyaluronic acid using the same. According to one aspect, the Streptococcus zooepidemicus SMT013 strain has increased hyaluronic acid production capacity and can be used to produce hyaluronic acid.

The present application relates to the animal medical technology field, especially to the Streptococcus suis strain and the vaccine thereof for prevention and treatment, and provides Streptococcus suis type 2, type 3 and type 9 strains screened and obtained, and a trivalent inactivated vaccine prepared by mixing the three strains, which can safely and effectively prevent and protect against the attack of the three pathogenic bacteria of Streptococcus suis.

The present invention discloses use of Streptococcus thermophilus ST7 for modulating immunity, comprising using the Streptococcus thermophilus ST7 as an active ingredient for modulating immunity, wherein the Streptococcus thermophilus ST7 are deposited under the accession Nos. BCRC911126 and DSM34255. By administering an effective dose of Streptococcus thermophilus ST7 to an individual, the expression level of IL-12p40 on cells can be increased, the gut microbiota can be modulated and the Firmicutes / Bacteroidetes ratio in the intestine increases to improve immunity and antiviral ability.

The application is directed to a method to manufacture pasta-filata cheese based on cultures comprising or consisting of either 1) at least a galactose-positive Streptococcus thermophilus strain as defined herein or 2) at least a Streptococcus thermophilus strain and a Lactococcus lactis strain, and to a stretched curd or cheese produced by this method. The application is also directed to a culture or kit-of-part comprising or consisting of a) a galactose-positive Streptococcus thermophilus strain as defined herein, and b) Lactococcus strain(s) and / or Lactobacillus helveticus strain(s).

The present disclosure is in the field of fermented food technology. It relates to new phage-resistant strains of the species Streptococcus thermophilus, compositions and fermented products comprising the strains, and methods for producing said fermented products.